Compounds related to the natural hormone glucagon-like peptide-1 (GLP-1) have become a hot new class of diabetes drug. GLP-1 is responsible for reducing blood sugar levels when they are too high, and its effects delay the need to move onto insulin injections.
All the major insulin players are aggressively pursuing this target. Eli Lilly & Co. outbid a number of drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?